



Life Sciences

Life Sciences supports promising companies in the life sciences sector. Gimv's characteristic long-term approach is particularly valuable in this capital-intensive sector, which is marked by cyclical fluctuations. The period between initial investment and exit is often long and unpredictable. To maximize return on investment and create short and long-term value for the companies we invest in, Life Sciences is committed to active involvement at Board of Director level.

Investment focus

The Life Sciences division supports innovative biotech companies developing first-in-class or best-in-class products for growth markets, active in various areas

- therapeutics;
- diagnostics;
- medical devices;
- technologies to be applied in agriculture or in white biotech.

Investment criteria

Gimv invests in companies

- led by committed, ambitious management teams;
- developing innovative first-in-class or best-in-class products or services;
- having a sustainable competitive advantage.

Investments

Abylnx, Actogenix, Ambit, Antisoma, Astex Therapeutics, Ceres, ChemoCentryx, Endosense, Innate Pharma, Movetis, Nereus Pharmaceuticals, PamGene, Plexxikon, Pronota, Prosensa, Santhera

Investment team

- **Patrick Van Beneden**
Executive Vice President Life Sciences
- **Jim Van heusden**
Executive Investment Manager
- **Christophe Van Vaeck**
Senior Investment Manager

The Life Sciences division is supported by an in-house legal team.



Success stories



About Gimv

- European investment firm established in 1980
- EUR 1.7 billion capital under management
- listed on Euronext Brussels (share code GIMB)
- strong international network
- experienced teams
- 4 offices: Belgium (Antwerp), The Netherlands (The Hague), France (Paris) and Germany (Frankfurt)

Solid structure

Buyouts & Growth

- Belgium
- Netherlands
- France
- Germany (Halder)

Venture Capital

- Technology
- Cleantech
- Life Sciences

Funds & Joint Ventures

- **Gimv-XL fund:** investments in larger growth companies in Flanders
- **Gimv-Agri+:** investments in the agricultural sector in the Benelux and neighbouring countries
- **Central Europe & Russia:** private equity investments in, among others, Russia via Eagle Capital Partners
- **DG Infra+:** investments in infrastructure and related assets in the Benelux
- **Other funds:** in, among others, the UK and Scandinavia